FMR1 and fragile X syndrome: Although the overall therapeutic efficacy in FXS was negative, a post-hoc analysis found significant therapeutic efficacy in 7 patients who had full FMR1 promoter methylation, but no response in 18 patients with partial promoter methylation [5,20].